ArticleFrontiers in endocrinology2021
Global, Regional, and National Burden of Diabetes-Related Chronic Kidney Disease From 1990 to 2019.
Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
177 citing papers in PubMed, 10 syntheses or guidelines pooled it, 304 citations in OpenAlex.
- Gestational Diabetes and Long-Term Risk of Maternal Kidney Disease: Systematic Review and Meta-Analysis of Population Base Cohort Studies.Endocrinology, diabetes & metabolism · 2026Pooled it
- The impact of sleep disturbances in individuals with comorbid diabetes and chronic kidney disease: a systematic review.Sleep & breathing = Schlaf & Atmung · 2025Pooled it
- Potential diagnostic value of microRNAs in vascular complications of diabetes: A systematic review and meta-analysis.Journal of endocrinological investigation · 2025Pooled it
- Comparative efficacy and safety of finerenone in diabetic kidney disease: a meta-analysis of Asian and non-Asian populations.BMC nephrology · 2025Pooled it
- Associations of genetic factors with vascular diabetes complications: an umbrella review.Journal of global health · 2025Pooled it
- Prevalence and Treatment Patterns of Anaemia in Individuals With Chronic Kidney Disease Across Asia: A Systematic Review and Meta-Analysis.Nephrology (Carlton, Vic.) · 2025Pooled it
- Association between the gut microbiota and diabetic nephropathy: a two-sample Mendelian randomization study.Renal failure · 2024Pooled it
- Renal functional outcomes after nephrectomy in patients with localized renal cell carcinoma and diabetes mellitus: a systematic review and meta-analysis.International urology and nephrology · 2024Pooled it
- Risk Prediction Score for Chronic Kidney Disease in Healthy Adults and Adults With Type 2 Diabetes: Systematic Review.Preventing chronic disease · 2023Pooled it
- Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Effect of intensive water-salt diet nursing intervention on blood pressure and volume load in patients with chronic renal failure.Renal failure · 2025Trial
- Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial.Annals of medicine · 2025Trial
- Trial
- Risk prediction of the progression of chronic kidney disease stage 1 based on peripheral blood samples: construction and internal validation of a nomogram.Renal failure · 2023Trial
- Tandem mass tag-based serum proteomic profiling revealed diabetic foot ulcer pathogenesis and potential therapeutic targets.Bioengineered · 2022Trial
- Determinants of hypoglycemia and hospitalization among hemodialysis patients with type 2 diabetes: insights from a multicenter study in a resource-limited healthcare system.Renal failure · 2026Article
- The mediating effect role of methylmalonic acid on the association between oxidative balance score and diabetic kidney disease: a cross-sectional study from NHANES 2011-2014.Renal failure · 2026Article
- Integrative multi-omics analysis identifies VCAN and ESM1 as candidate cell-type-associated biomarkers of NET-related glomerular injury in diabetic kidney disease.Renal failure · 2026Article
- Deubiquitinating enzymes in kidney diseases: Molecular mechanisms, pathological roles and therapeutic opportunities (Review).Molecular medicine reports · 2026Review
- Network pharmacology, single-cell transcriptomics, machine learning and experimental validation identifying CHEK2 and HPGD as key therapeutic targets of berberine in diabetic nephropathy.Functional & integrative genomics · 2026Article
117 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) is a public health problem largely caused by diabetes. The epidemiology of diabetes mellitus-related CKD (CKD-DM) could provide specific support to lessen global, regional, and national CKD burden. Methods: Data were derived from the GBD 2019 study, including four measures and age-standardized rates (ASRs). Estimated annual percentage changes and 95% CIs were calculated to evaluate the variation trend of ASRs. Results: Diabetes caused the majority of new cases and patients with CKD in all regions. All ASRs for type 2 diabetes-related CKD increased over 30 years. Asia and Middle socio-demographic index (SDI) quintile always carried the heaviest burden of CKD-DM. Diabetes type 2 became the second leading cause of CKD and CKD-related death and the third leading cause of CKD-related DALYs in 2019. Type 2 diabetes-related CKD accounted for most of the CKD-DM disease burden. There were 2.62 million incident cases, 134.58 million patients, 405.99 thousand deaths, and 13.09 million disability-adjusted life-years (DALYs) of CKD-DM worldwide in 2019. Age-standardized incidence (ASIR) and prevalence rate (ASPR) of type 1 diabetes-related CKD increased, whereas age-standardized death rate (ASDR) and DALY rate decreased for females and increased for males. In high SDI quintile, ASIR and ASPR of type 1 diabetes-related CKD remained the highest, with the slowest increase, whereas the ASDR and age-standardized DALY rate remained the lowest there. In high SDI quintile, ASIR of type 2 diabetes-related CKD was the highest, with the lowest increasing rate. In addition, type 2 diabetes-related CKD occurred most in people aged 80-plus years worldwide. The main age of type 2 diabetes-related CKD patients was 55-64 years in Asia and Africa. The prevalence, mortality, and DALY rate of type 2 diabetes-related CKD increased with age. As for incidence, there was a peak at 80 years, and after age of 80, the incidence declined. CKD-DM-related anemia was mainly in mild to moderate grade. Conclusions: Increasing burden of CKD-DM varied among regions and countries. Prevention and treatment measures should be strengthened according to CKD-DM epidemiology, especially in middle SDI quintile and Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.